Yineng Pharma has achieved a significant milestone by being named to the "Top 100 Innovative Medicine and Biological Products" list at the Future Healthcare 100 Conference held in Shanghai. This recognition underscores the company's advancements in AI-powered Traditional Chinese Medicine (TCM) research and development, positioning it as a leader in the digitization of TCM.
The Future Healthcare 100 Conference is a prominent event in China's health sector, attracting over 5,000 professionals, including government officials and industry leaders. The "Top 100" list serves as a benchmark for pharmaceutical innovation, evaluating companies based on technological innovation, R&D capabilities, industrial transformation, and growth potential. Yineng Pharma's inclusion reflects its robust R&D infrastructure, which includes a dedicated expert network and advanced facilities invested with over 200 million RMB.
Yineng has pioneered the integration of AI into TCM, enhancing the drug development process through data-driven methodologies. This shift from traditional experience-based practices to a more scientific approach has led to shorter R&D cycles and reduced costs for partners. The company is also establishing industry standards for digital TCM, further demonstrating its commitment to modernizing the field.
As it moves forward, Yineng Pharma aims to solidify its position as a global leader in digital TCM innovation. By merging ancient practices with modern technology, the company is set to showcase the potential of Chinese biotech on an international scale, reinforcing the relevance of TCM in contemporary healthcare.